Abstract
COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 in vitro and also clinically to treat this disease. This review article discusses the main antiviral strategies currently employed and summarizes reported in vitro and in vivo efficacies of key antiviral compounds in use.
Keywords:
COVID-19; SARS-CoV-2; antiviral; clinical trials; coronavirus; pandemic.
MeSH terms
-
Animals
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
BCG Vaccine / therapeutic use
-
Betacoronavirus / chemistry
-
Betacoronavirus / physiology*
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / physiopathology
-
Coronavirus Infections / virology
-
Drug Repositioning
-
Host-Pathogen Interactions / drug effects
-
Host-Pathogen Interactions / immunology
-
Humans
-
Immunologic Factors / therapeutic use
-
Inhibitory Concentration 50
-
Measles-Mumps-Rubella Vaccine / therapeutic use
-
Mice
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / physiopathology
-
Pneumonia, Viral / virology
-
SARS-CoV-2
-
Treatment Outcome
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
BCG Vaccine
-
Immunologic Factors
-
Measles-Mumps-Rubella Vaccine